Why Atrium Therapeutics, Inc.’s (RNA) Stock Is Up 6.02%
As of Thursday, November 19, Atrium Therapeutics, Inc.’s RNA share price has surged by 6.02%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Tudor Pop
Rosalio Madrigal
Michael Rose
Rosalio Madrigal
| Share Statistics | RNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $150.6 | $212.8 | 27% |
|
| Shares Out (Mil) | 17.0 | 55.2 | 28% |
|
| Institutional Ownership | 95.8% | 93.3% | 68% |
|
| Float (Mil) | 19.5 | 40.8 | 28% |
|
| Beta | na | 1.03 | na |
|
| Avg Daily Volume (000s) | 211 | 559 | 45% |
|
| Price Change (52-week) |
na | 40.3% | na |
|
| Growth | RNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.5%) | na |
|
| EPS (5yr) | na | 15.4% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($1.270) | ($3.170) | ($5.780) | |
| Month Ago EPS | ($1.370) | ($3.610) | ($6.390) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($1.720) | ($4.550) | ($8.060) | |
| Year/Year Chg | 408.0% | (0.7%) | 67.0% | |
| Financials | RNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $39 | $40 | 18% |
|
| Net Income (TTM) (Mil) | ($70) | ($44) | 13% |
|
| EPS (TTM) | ($4.282) | ($1.400) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($80) | ($34) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $45 | $-0 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($69) | $142 | 1% |
|
| Valuation | RNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.56 | 1.97 | 14% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | RNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (54.8%) | 67.6% | 2% |
|
| Net Margin | (180.9%) | (50.8%) | 5% |
|
| ROA | (51.7%) | (47.4%) | 11% |
|
| ROE | (95.0%) | (51.4%) | 9% |
|
| Liabilities to Assets | 22.3% | 29.6% | 15% |
|
| F-Score | 3 | 3 | na |
|
Atrium Therapeutics, Inc. did not pass any screens on 11/19/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors